Synonyms: AB 103 | AB103 | p2TA
Compound class:
Peptide
Comment: Reltecimod is a mimetic peptide that prevents binding of bacterial superantigens to the host target of CD28 [1]. It entered clinical development as an immunomodulating agent, with the aim of reducing the acute inflammatory response observed in patients with necrotizing soft tissue infections (NSTIs) that can lead to organ failure [2-3].
|
|
References |
1. Arad G, Levy R, Nasie I, Hillman D, Rotfogel Z, Barash U, Supper E, Shpilka T, Minis A, Kaempfer R. (2011)
Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol, 9 (9): e1001149. [PMID:21931534] |
2. Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, Moldawer LL, Demetriades D, Talving P, Schreiber M et al.. (2014)
A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial. JAMA Surg, 149 (6): 528-36. [PMID:24740134] |
3. Bulger EM, May AK, Robinson BRH, Evans DC, Henry S, Green JM, Toschlog E, Sperry JL, Fagenholz P, Martin ND et al.. (2020)
A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103). Ann Surg, 272 (3): 469-478. [PMID:32657946] |
4. Ramachandran G, Tulapurkar ME, Harris KM, Arad G, Shirvan A, Shemesh R, Detolla LJ, Benazzi C, Opal SM, Kaempfer R et al.. (2013)
A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by Streptococcus pyogenes. J Infect Dis, 207 (12): 1869-77. [PMID:23493729] |